Satellite Bio Reveals Pioneering Tissue Therapeutics, Bioengineered Tissues That Restore Organ Function, Bringing Hope Across Diseases
Summary
This next frontier of regenerative medicine has enormous potential to provide solutions for some of the most elusive diseases, said Dave Lennon, PhD, chief executive officer of Satellite Bio. Our SAT platform can be used with virtually any type of cell across a wide range of clinical applications, enabling the potential to create a broad pipeline of implantable Tissue Therapeutic solutions for patients.Satellite Bio has an exclusive license to technology originating in the labs of Sangeeta Bhatia, MD, PhD, director, Center for Nanomedicine, Massachusetts Institute of Technology and Christopher Chen, MD, PhD, director, Biological Design Center, Boston University. Lande-Diner, a scientist, innovator and life sciences entrepreneur, brings deep expertise in company creation and early operationalization across technologies and therapeutic areas. Prior to joining Satellite Bio, she was part of the Flagship Pioneering ecosystem where she was on the founding teams of Valo Health, Omega Therapeutics, Inari Agriculture and Epiva/Evelo Biosciences. These tissues, called Satellites, can deliver the comprehensive cellular response needed to repair or even replace critical organ functions in patients with diseases caused by the interaction of genetic and environmental factors.